Pharmafile Logo
Pharmafocus logo
Advanced Search

FDA

Showing 15 posts of 1444 posts found.

FDA approves Novartis’ heart failure drug Entresto

February 17, 2021
Research and Development FDA, Novartis

The FDA has approved Novartis’ Entresto (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalisation for heart failure in …

News
ipos0_l

FDA approves Regeneron’s Evkeeza for HoFH

February 12, 2021
Medical Communications FDA, Regeneron

The FDA has approved Regeneron’s Evkeeza (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat …

News
fdaoutsideweb

FDA approves Sanofi’s Libtayo for advanced basal cell carcinoma

February 10, 2021
Research and Development Cancer, FDA, Sanofi

The FDA has approved Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell …

News
gocovri

Adamas’ Parkinson’s drug gets US marketing authorisation for second indication

February 2, 2021
Manufacturing and Production Adamas Pharmaceuticals, FDA

The FDA has granted marketing authorisation for a second indication for Adamas Pharmaceuticals’ Gocovri (amantadine) extended release capsules. The drug …

News
janssen_latest_logo_on_sign

FDA approves Janssen’s AL amyloidosis drug

January 18, 2021
Sales and Marketing FDA, Janssen

The FDA has approved Janssen’s DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone …

News

Novartis’ ligelizumab granted FDA Breakthrough Therapy Designation

January 14, 2021
FDA, Novartis

The FDA has granted Novartis’ ligelizumab Breakthrough Therapy Designation for the treatment of chronic spontaneous urticaria (CSU) in patients who …

News
astrazeneca_sign_sky

AstraZeneca’s Farxiga granted Priority Review by FDA

January 6, 2021
Research and Development AstraZeneca, FDA, farxiga

AstraZeneca’s Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney …

News
astrazeneca_plaque

AstraZeneca’s cancer drug Tagrisso gets FDA approval

December 21, 2020
Sales and Marketing AstraZeneca, Cancer, FDA

The FDA has approved AstraZeneca’s Tagrisso (osimertinib) for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated …

News
fda2outsideweb

Moderna’s COVID-19 vaccine receives emergency approval from FDA

December 21, 2020
Sales and Marketing COVID-19, FDA, Moderna, US, Vaccine

Moderna has announced that the FDA yesterday authorised the emergency use of mRNA-1273, the biotechnology company’s vaccine against COVID-19 in …

News

FDA says Pfizer vaccine vials contain extra doses, boosting US supply

December 17, 2020
Sales and Marketing COVID-19, FDA, Pfizer, Vaccine

The FDA has announced that extra doses contained in Pfizer COVID-19 vaccine vials could expand America’s supply of the jab …

News
dw-anzcxqaqavhl

FDA panel backs Novartis’ Entresto for different form of heart disease

December 16, 2020
Research and Development FDA, Novartis, heart failure

Novartis’ heart failure drug Entresto has received recommendation from the FDA’s Cardiovascular and Renal Drugs Advisory Committee for use in …

News
fdaoutsideweb

FDA issues emergency use authorisation for Pfizer-BioNTech vaccine

December 14, 2020
Sales and Marketing COVID-19, FDA, US, Vaccine

The US Food and Drug Administration has approved the Pfizer-BioNTech COVID-19 vaccine for emergency use in those aged 16 and …

News

FDA advisory panel recommends US approval of Pfizer/BioNTech’s COVID-19 vaccine

December 11, 2020
Medical Communications, Sales and Marketing COVID-19, FDA, Vaccine

An advisory panel on behalf of the FDA has strongly recommended that Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 be approved …

News
dw-anzcxqaqavhl

FDA approves Novo Nordisk’s Saxenda for adolescent obesity

December 7, 2020
Sales and Marketing FDA, Novo Nordisk, saxenda

The FDA has awarded US approval to Novo Nordisk’s Saxenda (liraglutide) 3mg injection to treat obesity in patients between the …

News

FDA approves BioCryst’s Orladeyo for reducing hereditary angioedema attacks

December 4, 2020
Medical Communications, Sales and Marketing BioCryst, FDA, Orladeyo

BioCryst has scored FDA for its therapy Orladeyo (berotralstat) for reducing or preventing hereditary angioedema (HAE) attacks in patients over …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026